Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 2/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | TACR2 | P21452 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007584 | 1.00 | SLC7A5 (0.53) | SLC7A5ESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL27807718 | 1.00 | SLC7A5 (0.53) | SLC7A5ESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL10522486 | 0.99 | SLC7A5 (0.51) | SLC7A5ESR1LMNACYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL16007657 | 0.99 | SLC7A5 (0.51) | SLC7A5ESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL7744532 | 0.99 | SLC7A5 (0.51) | SLC7A5ESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL1270995 | 0.99 | SLC7A5 (0.51) | SLC7A5ESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL7744530 | 0.99 | SLC7A5 (0.51) | SLC7A5ESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL1270832 | 0.99 | SLC7A5 (0.51) | SLC7A5ESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL5250950 | 0.99 | SLC7A5 (0.51) | SLC7A5ESR1LMNACYP1A2CYP2D6 | |
| SCHEMBL5250954 | 0.99 | SLC7A5 (0.51) | SLC7A5ESR1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122421-A1 | Crystallization of amino acids using ultrasonic agitation | BECHTEL SIEGFRIED | 2006-06-08 | — | — | US | claimed |
| EP-1461307-A2 | CRYSTALLIZATION OF AMINO ACIDS USING ULTRASONIC AGITATION | Abbott GmbH & Co. KG (DE) | 2004-09-29 | — | — | EP | claimed |
| US-20030166726-A1 | Crystallization of amino acids using ultrasonic agitation | ABBOTT GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | claimed |
| WO-2003057717-A2 | CRYSTALLIZATION OF AMINO ACIDS USING ULTRASONIC AGITATION | ABBOTT GMBH & CO. KG (DE) | 2003-07-17 | — | — | WO | claimed |
| US-9962369-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9949952-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9783798-B2 | Site-specific incorporation of redox active amino acids into proteins | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3116489-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | Yu, Benjamin M. (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | SPRAYABLE HOLDINGS, INC. | 2016-11-03 | — | — | US | disclosed |
| EP-2964231-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORMS OF SOLUTION OR SUSPENSION | Yu, Benjamin M. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-9211249-B2 | Methods and compositions for transdermal delivery of caffeine in the form of solutions or suspensions | SPRAYABLE HOLDINGS, INC. | 2015-12-15 | — | — | US | disclosed |
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | SPRAYABLE HOLDINGS, INC. | 2015-09-17 | — | — | US | disclosed |
| EP-1687401-A2 | SITE-SPECIFIC INCORPORATION OF REDOX ACTIVE AMINO ACIDS INTO PROTEINS | The Scripps Research Institute (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060122421-A1 | Crystallization of amino acids using ultrasonic agitation | BECHTEL SIEGFRIED | 2006-06-08 | — | — | US | disclosed |
| US-6992216-B2 | Crystallization of amino acids using ultrasonic agitation | ABBOTT GMBH & CO. KG (DE) | 2006-01-31 | — | — | US | disclosed |
| US-20050227318-A1 | Site-specific incorporation of redox active amino acids into proteins | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-10-13 | — | — | US | disclosed |
| WO-2005038002-A2 | SITE-SPECIFIC INCORPORATION OF REDOX ACTIVE AMINO ACIDS INTO PROTEINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1461307-A2 | CRYSTALLIZATION OF AMINO ACIDS USING ULTRASONIC AGITATION | Abbott GmbH & Co. KG (DE) | 2004-09-29 | — | — | EP | disclosed |
| US-20030166726-A1 | Crystallization of amino acids using ultrasonic agitation | ABBOTT GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003057717-A2 | CRYSTALLIZATION OF AMINO ACIDS USING ULTRASONIC AGITATION | ABBOTT GMBH & CO. KG (DE) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | MTNR1A, MTNR1B, CYP27B1 | SLC7A5 3782/4885ESR1 63/4885LMNA 2340/4885 |
| US-20030166726-A1 | Crystallization of amino acids using ultrasonic agitation | DNPEP, ANPEP, UBAP2 | SLC7A5 327/4885ESR1 4652/4885LMNA 3179/4885 |
| US-20050227318-A1 | Site-specific incorporation of redox active amino acids into proteins | AARS1, OSGEP, EPRS1 | SLC7A5 569/4885ESR1 3517/4885LMNA 4354/4885 |
| US-20060122421-A1 | Crystallization of amino acids using ultrasonic agitation | DNPEP, ANPEP, UBAP2 | SLC7A5 327/4885ESR1 4652/4885LMNA 3179/4885 |
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | TES, CCR7, CES2 | SLC7A5 2194/4885ESR1 1226/4885LMNA 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.